From MarketBeat:

Adaptimmune Therapeutics CEO, Adrian Rawcliffe, sold 11,945 shares of the company’s stock at an average price of $0.84, totaling $10,033.80 on January 11th. Insider reports show the chief executive officer now owns 18,395 shares of the company stock, valued at $15,451.80. The transaction was disclosed in a filing with the SEC.

Adaptimmune Therapeutics stock traded down 6.5% on Friday, reaching $0.82 a share. The company’s stock has been volatile, with a 12-month low of $0.42 and a high of $2.04. Its 50-day simple moving average is $0.58 and its 200-day simple moving average is $0.72. The company’s market cap is $818.14 million.

Adaptimmune Therapeutics reported a 12-month revenue of $7.32 million, which met the consensus estimate. The company had revenue of $5.00 million, beating the consensus estimate. The biotechnology company had a negative net margin of 133.94% and a negative return on equity of 118.47%. Analysts project that Adaptimmune Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutions investors and hedge funds have taken a keen interest in Adaptimmune Therapeutics. Barclays PLC, Black Maple Capital Management, Baillie Gifford & Co., Marquette Asset Management, and Acadian Asset Management have all made significant investments in the company, owning 14.55% of the company’s stock.

According to StockNews.com, a research note on December 29th issued a “hold” rating for Adaptimmune Therapeutics stock. As other institutional investors maneuver price targets, analysts anticipate a more favorable outcome.

Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company, undertaking phase II clinical trials for cancer treatments. If you are considering investing in Adaptimmune Therapeutics, it is essential to take into account the company’s latest business updates and key financial indicators.



Read more: Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Sells $10,033.80 in Stock